Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.14 USD | +2.09% | +4.51% | -12.61% |
04-18 | NeoGenomics, Inc. Announces Senior Leadership Promotions | CI |
04-18 | NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics | CI |
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- With an enterprise value anticipated at 3.19 times the sales for the current fiscal year, the company turns out to be overvalued.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.61% | 1.81B | C- | ||
-16.58% | 8.25B | B+ | ||
+39.20% | 3.58B | C+ | ||
-39.11% | 2.46B | B- | ||
-8.06% | 2.46B | - | ||
-6.82% | 2.38B | B- | ||
-19.01% | 1.55B | A- | ||
-40.66% | 1.21B | C+ | ||
+7.56% | 1.11B | B+ | ||
-15.34% | 1.03B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEO Stock
- Ratings NeoGenomics, Inc.